SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-007020
Filing Date
2023-03-09
Accepted
2023-03-09 16:10:56
Documents
49
Period of Report
2023-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20230131.htm   iXBRL 10-Q 1937693
2 EX-31.1 kalv-ex31_1.htm EX-31 21876
3 EX-31.2 kalv-ex31_2.htm EX-31 19713
4 EX-32.1 kalv-ex32_1.htm EX-32 14530
  Complete submission text file 0000950170-23-007020.txt   5499722

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20230131_cal.xml EX-101.CAL 44973
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230131.xsd EX-101.SCH 27049
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230131_pre.xml EX-101.PRE 162086
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230131_lab.xml EX-101.LAB 240457
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20230131_def.xml EX-101.DEF 55887
43 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230131_htm.xml XML 936676
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 23719848
SIC: 2834 Pharmaceutical Preparations